News
Podcast
Author(s):
The UCLA hepatologist discusses the current treatment landscape, prospects for improved diagnostics, and the overlap syndrome live from ACG 2023.
0:12 Intro
1:24 Challenges in autoimmune hepatitis
3:30 Patient demographics
4:25 Diagnostic challenges
6:35 What is overlap syndrome?
8:04 Mysteries behind immune dysregulation
9:05 Promising drugs in investigation
10:51 The BAFF receptor target
11:41 Infliximab & rituximab
12:38 An autoimmune hepatitis wishlist
15:29 Outro
Autoimmune hepatitis (AIH), a rare liver disease characterized by an unclear driver of inflammation, is historically challenged by limited clinical understanding, a slow development of treatment options in investigation, and a nonetheless concerning prognosis for affected adults and children.
While some prospects are in development to aid specialists in adequately identifying risk factors for, diagnosing and treating AIH, education and communication on those developments is vital.
In an interview with HCPLive during the American College of Gastroenterology (ACG 2023) Annual Scientific Meeting in Vancouver, BC this week, Gina Choi, MD, associator clinical professor of medicine and surgery at UCLA Health, discussed the ins and outs of modern autoimmune liver disease research and development.
Including the treatment pipeline and current standards for diagnostics, Choi additionally discussed the sociodemographic and pathophysiological traits of AIH burden—as well as the lesser-known overlap syndrome.
